BASIC PRINCIPLES 1. Mechanisms of Action of Calcium Antagonists (David J. Triggle, PhD) 2. Alterations in Cardiovascular Cation Metabolism in the Cardiometabolic Syndrome (Dmitri Kirpichnikov, Samy McFarlane, Nate Winer, and James Sowers) 3. Endothelial Regulation of Vascular Tone and Growth: Role of Calcium Antagonists (Thomas F. Luscher, MD, and Rene R. Wenzel, MD, and Georg Nool, MD) 4. Endothelial Dysfunction: Evolving Perspectives for Pathogenesis & Calcium Antagonist Therapy (Massimo Volpe) CLINICAL PHARMACOLOGY 5. Pharmacokinetics of Calcium Antagonists: Implications for Therapy (Henry L. Elliott, MD, FRCP, and Peter A. Meredith, PhD) 6. Calcium Antagonists and the Cytochrome P450 System (Domenic Sica) 7. Time-Effect Profile and Duration of Action of Calcium Antagonists: Implications for Rational Management (Faiez Zannad) 8. Ambulatory Blood Pressure Monitoring in the Evaluation ofAntihypertensive Treatment with Calcium Antagonists (Giuseppe Mancia) 9. Controlled-Release Formulations of the Calcium Antagonists (William J. Elliott, MD, PhD) 10. Novel Therapeutic Applications for Calcium Antagonists: Atherosclerotic Plaque Stabilization (R. Preston Mason) METABOLIC EFFECTS 11. Insulin and Glucoregulatory Hormones: Implications for Antihypertensive Therapy (Dalila B. Corry, MD, and Michael L. Tuck, MD) 12. Effects of Calcium Antagonists on Lipids (Ronald B. Goldberg, MD, and Hermes Florez, MD, MPH) THE HEART 13. Effect of Calcium Antagonists on Hemodynamics, Left Ventricular Mass and Myocardial Flow Reserve (Robert A. Phillips, MD, PhD and Joseph Diamond, MD) 14. Cardiac Effects of Calcium Antagonists in Hypertension (Ehud Grossman, MD, and Franz H. Messerli, MD) 15. Calcium Antagonists and Myocardial Ischemia (George W. Vetrovec, MD) 16. The Therapeutic Potential of Calcium Antagonists for Lethal Ventricular Arrhythmias: Ischemia-selective Antagonists May Prevent Ventricular Fibrillation (George E. Billman, PhD) 17. The Clinical Antiarrhythmic Effectiveness of Calcium Antagonists (Simon Chakko, MD) 18. Are Calcium Antagonists Proarrhythmic? (Simon Chakko, MD, and Murray Epstein, MD, FACP) HYPERTENSION 19. Calcium Antagonists in the Management of Hypertension (Murray Epstein, MD, FACP) 20. Hemodynamic Effects of Calcium Antagonists in Hypertension (Per Lund-Johansen, MD) 21. Systolic Blood Pressure and Pulse Pressure as Determinants of Cardiovascular Risk: Implications for Rational Therapy (William White) 22. Arterial Compliance and Effect of Calcium Antagonists (Gerard M. London, MD, and Michel E. Safar, MD) 23. The Role of Calcium Antagonists in Cardiovascular Prevention: A Meta-analysis of Recent Trials (Ji-Guang Wang, and Jan Staessen) SPECIAL POPULATIONS 24. Diabetic Nephropathy: Focus on the Renin-Angiotensin System and Calcium Channel Blockade (Murray Epstein, MD, FACP, and Mark E. Cooper, MD, FRACP) 25. Calcium Antagonists: Are They All Created Equal in Regard to Slowing Progression of Diabetic Nephropathy? (George L. Bakris, MD, FACP, and Munavvar Izhar, MD) 26. Calcium Antagonists as Antihypertensive Agents in African-American Patients (John M. Flack, MD, MPH) 27. Drug Responsiveness and Side Effects: Lessons from Chinese Populations (Juliana Chan, MD, Wilson Y.S. Leung, Bpharm, and Julian A.J.H. Critchley, PhD) 28. Pharmacogenetic Markers of Hypertension: Pathogenesis and Responses to Therapy (Stephen T. Turner, MD) 29. Calcium Antagonists in Elderly Patients with Systemic Hypertension (William H. Frishman, MD, and Atif Qureshi, MD) 30. Management of High Blood Pressure in Pregnancy (Marshall D. Lindheimer, MD, and Dr. Edgardo Abalos) CALCIUM ANTAGONISTS IN THE TREATMENT OF NONCARDIOVASCULAR DISORDERS 31. Calcium Antagonists and Central Nervous System Diseases (Alexander Scriabine, MD) CALCIUM ANTAGONISTS AND THE KIDNEY 32. Renal Hemodynamic Effects of Calcium Antagonists (Koichi Hayashi, MD, PhD, Takao Saruta, MD, PhD, and Murray Epstein, MD, FACP) 33. Effects of Calcium Antagonists on Vasoactive Hormones (Jesus Egido, MD, PhD, Jose Tunon, MD, Nieves Tarin, MD) 34. The Clinical Utility of Calcium Antagonists in Renal Transplant Recipients (Matthew R. Weir, MD) 35. Calcium Antagonists and the Kidney; Implications for Renal Protection (Murray Epstein, MD, FACP) 36. Ambulatory Blood Pressure: Implications for Renal Dysfunction (Josep Redon) 37. Salt Sensitivity and Microalbumuria: Implications for Pathogenesis and Management (Vito Campese) 38. Calcium Antagonists and End-Stage Renal Disease: Pharmacokinetics and Pharmacodynamics (Domenic Sica) EMERGING PERSPECTIVES 39. Fixed-dose Combination Therapy with Calcium Antagonists (Murray Epstein, MD, FACP, and Bernard Waeber, MD) 40. Inproving the Cost-effectiveness of Treating Hypertension (William J. Elliott, MD, PhD) 41. Effects of Calcium Antagonists on Atherosclerosis (Jose Tunon, Nieves Tarin, and Jesus Egido) 42. Sympathoinhibitory and Sympathoexcitatory Effects of Dihydropyridine Calcium Antagonists (Frans H. H. Leenen, MD, PhD, FRCPC) 43. Apoptosis and Risk with the Use of Calcium Antagonists(Nanette Bishopric) 44. Safety of Calcium Antagonists as Antihypertensive Agents: An Update (Murray Epstein, MD, FACP)
